A suspected plague death in Russia has renewed attention on the rare infection. Here's how to spot pneumonic plague and which antibiotics the CDC recommends.
|Articles|October 21, 2021
Daily Medication Pearl: Glecaprevir and Pibrentasvir (Mavyret) for Hepatitis C
Author(s)Saro Arakelians, PharmD
Mavyret is indicated for the treatment of patients with chronic hepatitis C virus without cirrhosis or with compensated cirrhosis.
Advertisement
Medication Pearl of the Day: Glecaprevir and Pibrentasvir (Mavyret)
Indication: Mavyret is a fixed-dose combination of glecaprevir and pibrentasvir, indicated for the treatment of adult and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) genotype (GT) 1, 2, 3, 4, 5 or 6 infections without cirrhosis or with compensated cirrhosis.
Insight:
- Dosing: Three tablets taken at the same time orally once daily (total daily dose: glecaprevir 300 mg and pibrentasvir 120 mg) with food.
- Dosage form: Tablets 100 mg glecaprevir and 40 mg pibrentasvir. Oral pellets 50 mg glecaprevir and 20 mg pibrentasvir.
- Adverse events (AEs): In patients receiving Mavyret, the most reported AEs (greater than 10%) are headache and fatigue.
- Mechanism of action: Mavyret is a fixed-dose combination of glecaprevir, an HCV NS3/4A protease inhibitor, and pibrentasvir, an HCV NS5A inhibitor.
- Manufacturer: AbbVie
Sources:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
SubscribeAdvertisement
Related to this article
The gap is not a paperwork inconvenience—it is a cash flow problem with clinical consequences.
Despite the controversy surrounding mRNA's role in the COVID-19 response, the technology's broader promise—to prevent, treat, and even cure a host of diseases—is coming into focus.
Age is the leading factor in influenza vaccine selection, and vaccination remains effective well beyond the ideal September-to-October window.
Tor Härnqvist, MD, discusses immune testing after invasive pneumococcal disease, serotype-informed vaccine selection, and pharmacists' role in supporting patients on immunoglobulin therapy.
Decades after cisplatin's approval, platinum-based chemotherapy continues to anchor treatment regimens across tumor types, new research finds.
Invasive pneumococcal disease may be the first sign of undiagnosed blood cancers and antibody deficiencies in adults, a new study finds.
Pharmacists can help overcome influenza vaccine hesitancy by correcting common misconceptions, routinely asking every patient about vaccination, and leveraging their standing as trusted health care professionals.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Rising Gallbladder Complications With GLP-1 Receptor Agonists Call for Closer Pharmacist Monitoring
2
Pneumonic Plague: Symptoms, Antibiotics, and Current US Risk
3
Inside the New Consensus Recommendations for Acute Stroke Care
4
The Coding Gap Nobody Prices In: Why New Specialty Drugs Launch Reimbursement-Blind
5